Finally, we will discuss the novel concept of therapy-induced upregulation of AnxA6 especially in basal-like TNBC cells with low AnxA6 levels (AnxA6-low TNBC cells) as another mechanism for acquired resistance of this hard-to-treat breast cancer subtype to TKIs. This evidence concerns the gene ANXA6 and breast cancer.